Creating jobs: Abbott's $500 million investment in US manufacturing

Abbott recently announced plans to build a new cardiovascular device manufacturing facility in Georgia, which is expected to be completed in 2028. The announcement follows strong second-quarter performance for the company’s cardiovascular business, with Electrophysiology, Heart Failure and Structural Heart all delivering double-digit organic sales growth. 

The Georgia facility is Abbott’s second investment in U.S. manufacturing in 2025. In April, we announced new investments in U.S. manufacturing and R&D that will expand Abbott’s transfusion diagnostics business, which screens more than 50% of the global blood and plasma supply. Those investments, totaling $500 million, will create 300 new American jobs. 

These developments further Abbott's long history of investment in American innovation. Over the last five years, the company has invested more than $15 billion in U.S. operations, including manufacturing, equipment, and R&D. With world headquarters in north suburban Chicago, 35 manufacturing sites in 15 states and 43 R&D sites in 13 states, Abbott has a larger presence in the U.S. than in any other country or region. Abbot has also made investments globally, as they operate their manufacturing and supply chain network to be resilient and close to customers served.

Entering a $1B market with next-generation molecular diagnostics

With these new investments in transfusion diagnostics manufacturing, Abbott will enter the molecular nucleic acid blood and plasma testing market, which is estimated to represent an approximately $1 billion market opportunity. To ensure the safety of recipients of blood component transfusions and plasma-derived therapies, donations must be screened for infectious diseases, such as HIV and hepatitis, as well as other pathogens using serology and molecular testing. Abbott’s current blood and plasma screening system, Alinity s, runs serology screening tests. The new Alinity n system will perform molecular testing, capable of detecting DNA and RNA for multiple pathogens. It’s a compact instrument intentionally designed with customers in mind. 

"Our transfusion medicine, R&D, medical affairs and marketing teams have visited key organizations around the world to understand their pain points, work to address unmet needs and ensure that this solution would serve the community in the best way," says Elizabeth Balthrop, vice president, Transfusion Medicine. "We've shared our advancements and our scientific breakthrough with leaders in the industry and the feedback they've provided us has been encouraging as they think about how to manage their blood and plasma supply."